ESR1 and breast carcinoma: An analysis conducted among 111 Swedish breast cancer patients younger than 37 years of age found a trend towards a higher survival rate, especially among those estrogen receptor-positive tamoxifen-treated patients that were homozygous for the rare Taq1 allele [35].